Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PALISADE BIO, INC.CUR · Entity 5803 | Director · Chief Executive Officer | November 07, 2017 | November 09, 2017 |
| SYNERGY PHARMACEUTICALS, INC.SGYP · Entity 164269 | Director | June 28, 2017 | June 30, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PALISADE BIO, INC.
Report date November 07, 2017 · Filed November 09, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock Purchase OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.12 · Expires 2027-11-07 | Direct | 100,000 |
Reported balance
After 2017-11-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-11-07 · Grant · Acquired 100,000 · Balance 100,000 F1: Represents a discretionary grant to Employee. The options vest quarterly on 2/718, 5/7/18, 8/7/18, and 11/7/18. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a discretionary grant to Employee. The options vest quarterly on 2/718, 5/7/18, 8/7/18, and 11/7/18.
SYNERGY PHARMACEUTICALS, INC.
Report date June 28, 2017 · Filed June 30, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $4.50 · Expires 2027-06-28 | Direct | 189,056 |
Reported balance
After 2017-06-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-06-28 · Grant · Acquired 62,500 · Balance 189,056 |
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CATALYST PHARMACEUTICALS, INC.
Report date July 15, 2026 · Filed July 17, 2026
Section 16 reporting ended · disclosed 2026-07-17. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.001 per shareSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-07-15 transaction · row 1
1 source rowRow 1 · 2026-07-15 · Disposition to issuer · Disposed 271,266 · Balance 0 F1: The reported securities were disposed of in connection with the consummation of the acquisition of the Issuer by Angelini Pharma S.p.A. (the "Merger") |
| Options to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $4.64 · Expires 2026-12-02 | Direct | 0 |
Reported balance
After 2026-07-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-07-15 · Disposition to issuer · Disposed 33,500 · Balance 0 F3: In connection with the consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share over the per-share price of such Option, multiplied by (y) the total number of shares subject to such Option. F5: Each Option was fully vested. |
| Options to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $3.42 · Expires 2027-12-30 | Direct | 0 |
Reported balance
After 2026-07-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-07-15 · Disposition to issuer · Disposed 30,000 · Balance 0 F3: In connection with the consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share over the per-share price of such Option, multiplied by (y) the total number of shares subject to such Option. F5: Each Option was fully vested. |
| Options to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $7.07 · Expires 2028-12-28 | Direct | 0 |
Reported balance
After 2026-07-15 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-07-15 · Disposition to issuer · Disposed 20,000 · Balance 0 F3: In connection with the consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share over the per-share price of such Option, multiplied by (y) the total number of shares subject to such Option. F5: Each Option was fully vested. |
| Options to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $18.59 · Expires 2029-12-27 | Direct | 0 |
Reported balance
After 2026-07-15 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-07-15 · Disposition to issuer · Disposed 15,000 · Balance 0 F3: In connection with the consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share over the per-share price of such Option, multiplied by (y) the total number of shares subject to such Option. F5: Each Option was fully vested. |
| Options to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $13.30 · Expires 2031-01-01 | Direct | 0 |
Reported balance
After 2026-07-15 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-07-15 · Disposition to issuer · Disposed 1,365,319 · Balance 0 F3: In connection with the consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share over the per-share price of such Option, multiplied by (y) the total number of shares subject to such Option. F6: Each Option or RSU, as applicable, vested in full in connection with the consummation of the Merger. |
| Options to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $21.12 · Expires 2031-11-21 | Direct | 0 |
Reported balance
After 2026-07-15 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-07-15 · Disposition to issuer · Disposed 491,160 · Balance 0 F3: In connection with the consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share over the per-share price of such Option, multiplied by (y) the total number of shares subject to such Option. F6: Each Option or RSU, as applicable, vested in full in connection with the consummation of the Merger. |
| Options to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $22.77 · Expires 2032-11-20 | Direct | 0 |
Reported balance
After 2026-07-15 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-07-15 · Disposition to issuer · Disposed 381,948 · Balance 0 F3: In connection with the consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share over the per-share price of such Option, multiplied by (y) the total number of shares subject to such Option. F6: Each Option or RSU, as applicable, vested in full in connection with the consummation of the Merger. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2029-01-01 | Direct | 0 |
Reported balance
After 2026-07-15 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-07-15 · Disposition to issuer · Disposed 126,316 · Balance 0 F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F4: In connection with the consummation of the Merger, each reported restricted stock unit ("RSU") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share, multiplied by (y) the number of shares subject to such RSU. F6: Each Option or RSU, as applicable, vested in full in connection with the consummation of the Merger. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2027-11-21 | Direct | 0 |
Reported balance
After 2026-07-15 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-07-15 · Disposition to issuer · Disposed 40,013 · Balance 0 F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F4: In connection with the consummation of the Merger, each reported restricted stock unit ("RSU") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share, multiplied by (y) the number of shares subject to such RSU. F6: Each Option or RSU, as applicable, vested in full in connection with the consummation of the Merger. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2028-11-20 | Direct | 0 |
Reported balance
After 2026-07-15 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-07-15 · Disposition to issuer · Disposed 115,283 · Balance 0 F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F4: In connection with the consummation of the Merger, each reported restricted stock unit ("RSU") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share, multiplied by (y) the number of shares subject to such RSU. F6: Each Option or RSU, as applicable, vested in full in connection with the consummation of the Merger. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities were disposed of in connection with the consummation of the acquisition of the Issuer by Angelini Pharma S.p.A. (the "Merger")
F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F3: In connection with the consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share over the per-share price of such Option, multiplied by (y) the total number of shares subject to such Option.
F4: In connection with the consummation of the Merger, each reported restricted stock unit ("RSU") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share, multiplied by (y) the number of shares subject to such RSU.
F5: Each Option was fully vested.
F6: Each Option or RSU, as applicable, vested in full in connection with the consummation of the Merger.
OPIANT PHARMACEUTICALS, INC.
Report date March 02, 2023 · Filed March 03, 2023
Section 16 reporting ended · disclosed 2023-03-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2023-03-02 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-03-02 · Disposition to issuer · Disposed 5,800 · Balance 2,000 F1: Disposed of pursuant to that certain Agreement and Plan of Merger between the Issuer, Indivior Inc., and Olive Acquisition Subsidiary, Inc., dated as of November 13, 2022 (the "Merger Agreement"), in exchange for a cash payment of $20.00 per share without interest thereon (the "Merger Consideration"). Row 2 · 2023-03-02 · Disposition to issuer · Disposed 2,000 · Balance 0 F2: Disposed of pursuant to the Merger Agreement in exchange for the Merger Consideration. The number of shares disposed of reflects 2,000 shares of Common Stock upon the acceleration of vesting of restricted stock units in accordance with the Merger Agreement. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.75 · Expires 2029-06-11 | Direct | 0 |
Reported balance
After 2023-03-02 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-03-02 · Disposition to issuer · Disposed 2,500 · Balance 0 F3: The option was cancelled pursuant to the Merger Agreement in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of disposed option shares. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.30 · Expires 2031-06-14 | Direct | 0 |
Reported balance
After 2023-03-02 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-03-02 · Disposition to issuer · Disposed 2,500 · Balance 0 F3: The option was cancelled pursuant to the Merger Agreement in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of disposed option shares. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.56 · Expires 2028-06-11 | Direct | 0 |
Reported balance
After 2023-03-02 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-03-02 · Disposition to issuer · Disposed 5,000 · Balance 0 F3: The option was cancelled pursuant to the Merger Agreement in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of disposed option shares. |
| Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $8.79 · Expires 2030-06-15 | Direct | 0 |
Reported balance
After 2023-03-02 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-03-02 · Disposition to issuer · Disposed 2,500 · Balance 0 F3: The option was cancelled pursuant to the Merger Agreement in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of disposed option shares. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to that certain Agreement and Plan of Merger between the Issuer, Indivior Inc., and Olive Acquisition Subsidiary, Inc., dated as of November 13, 2022 (the "Merger Agreement"), in exchange for a cash payment of $20.00 per share without interest thereon (the "Merger Consideration").
F2: Disposed of pursuant to the Merger Agreement in exchange for the Merger Consideration. The number of shares disposed of reflects 2,000 shares of Common Stock upon the acceleration of vesting of restricted stock units in accordance with the Merger Agreement.
F3: The option was cancelled pursuant to the Merger Agreement in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of disposed option shares.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 12, 2023 Filed May 16, 2023 21:01 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Exercise / conversionCommon Stock, par value $0.001 per share | 50,000 | $0.79 | $39,500.00 |
DisclosureSEC source: 0001161697-23-000293 · form4.xml · nonDerivative · entry 1 Daly Richard J · CIK 0001635393 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 148,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 02, 2023 Filed Mar 3, 2023 09:20 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | Disposition to issuerCommon Stock · Derivative | 2,500 | $0.00 Strike: $8.79 | $0.00 |
DisclosureSEC source: 0001385508-23-000071 · wf-form4_167785323994742.xml · derivative · entry 6 Daly Richard J · CIK 0001635393 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,500 shares Expires 2030-06-15 F3 · kind: The option was cancelled pursuant to the Merger Agreement in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of disposed option shares. F3 · derivative.exercise_date: The option was cancelled pursuant to the Merger Agreement in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of disposed option shares. Read SEC document |
| March 02, 2023 Filed Mar 3, 2023 09:20 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | Disposition to issuerStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $15.56 | $0.00 |
DisclosureSEC source: 0001385508-23-000071 · wf-form4_167785323994742.xml · derivative · entry 5 Daly Richard J · CIK 0001635393 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2028-06-11 F3 · kind: The option was cancelled pursuant to the Merger Agreement in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of disposed option shares. F3 · derivative.exercise_date: The option was cancelled pursuant to the Merger Agreement in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of disposed option shares. Read SEC document |
| March 02, 2023 Filed Mar 3, 2023 09:20 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | Disposition to issuerStock Option (right to buy) · Derivative | 2,500 | $0.00 Strike: $13.30 | $0.00 |
DisclosureSEC source: 0001385508-23-000071 · wf-form4_167785323994742.xml · derivative · entry 4 Daly Richard J · CIK 0001635393 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,500 shares Expires 2031-06-14 F3 · kind: The option was cancelled pursuant to the Merger Agreement in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of disposed option shares. F3 · derivative.exercise_date: The option was cancelled pursuant to the Merger Agreement in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of disposed option shares. Read SEC document |
| March 02, 2023 Filed Mar 3, 2023 09:20 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | Disposition to issuerStock Option (right to buy) · Derivative | 2,500 | $0.00 Strike: $12.75 | $0.00 |
DisclosureSEC source: 0001385508-23-000071 · wf-form4_167785323994742.xml · derivative · entry 3 Daly Richard J · CIK 0001635393 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,500 shares Expires 2029-06-11 F3 · kind: The option was cancelled pursuant to the Merger Agreement in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of disposed option shares. F3 · derivative.exercise_date: The option was cancelled pursuant to the Merger Agreement in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of disposed option shares. Read SEC document |
| March 02, 2023 Filed Mar 3, 2023 09:20 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | Disposition to issuerCommon Stock | 2,000 | $20.00 | $40,000.00 |
DisclosureSEC source: 0001385508-23-000071 · wf-form4_167785323994742.xml · nonDerivative · entry 2 Daly Richard J · CIK 0001635393 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · kind: Disposed of pursuant to the Merger Agreement in exchange for the Merger Consideration. The number of shares disposed of reflects 2,000 shares of Common Stock upon the acceleration of vesting of restricted stock units in accordance with the Merger Agreement. Read SEC document |
| March 02, 2023 Filed Mar 3, 2023 09:20 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | Disposition to issuerCommon Stock | 5,800 | $20.00 | $116,000.00 |
DisclosureSEC source: 0001385508-23-000071 · wf-form4_167785323994742.xml · nonDerivative · entry 1 Daly Richard J · CIK 0001635393 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 F1 · kind: Disposed of pursuant to that certain Agreement and Plan of Merger between the Issuer, Indivior Inc., and Olive Acquisition Subsidiary, Inc., dated as of November 13, 2022 (the "Merger Agreement"), in exchange for a cash payment of $20.00 per share without interest thereon (the "Merger Consideration"). Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 22:00 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Exercise / conversionRestricted Stock Units · Derivative | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001161697-23-000124 · form4.xml · derivative · entry 2 Daly Richard J · CIK 0001635393 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 310,500 Underlying: Common Stock · 4,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting. F2 · derivative.exercise_date: Derivative securities vest in equal tranches, 1/3rd on February 14, 2023, 1/3rd on February 14, 2024 and 1/3rd on February 14, 2025. F3 · derivative.expiration_date: Shares of common stock are required to be delivered to the Reporting Person within sixty days of vesting. The first tranche of shares was delivered on February 15, 2023. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 22:00 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Exercise / conversionCommon Stock, par value $0.001 per share | 4,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001161697-23-000124 · form4.xml · nonDerivative · entry 1 Daly Richard J · CIK 0001635393 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting. Read SEC document |
| December 27, 2022 Filed Dec 29, 2022 21:45 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | GrantRestricted Stock Units · Derivative | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001161697-22-000601 · form4.xml · derivative · entry 2 Daly Richard J · CIK 0001635393 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 314,500 Underlying: Common Stock · 4,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting. F1 · derivative.exercise_date: Derivative securities vest in equal tranches, 1/3rd on December 27, 2023, 1/3rd on December 27, 2024 and 1/3rd on December 27, 2025. F3 · derivative.expiration_date: Shares of common stock will be delivered to the Reporting Person upon vesting. Read SEC document |
| December 27, 2022 Filed Dec 29, 2022 21:45 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | GrantOptions to purchase common stock · Derivative | 15,000 | $0.00 Strike: $18.59 | $0.00 |
DisclosureSEC source: 0001161697-22-000601 · form4.xml · derivative · entry 1 Daly Richard J · CIK 0001635393 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 310,500 Underlying: Common Stock · 15,000 shares Expires 2029-12-27 F1 · derivative.exercise_date: Derivative securities vest in equal tranches, 1/3rd on December 27, 2023, 1/3rd on December 27, 2024 and 1/3rd on December 27, 2025. Read SEC document |
| December 06, 2022 Filed Dec 8, 2022 22:01 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Exercise / conversionRestricted Stock Units · Derivative | 1,334 | $0.00 | $0.00 |
DisclosureSEC source: 0001161697-22-000570 · form4.xml · derivative · entry 2 Daly Richard J · CIK 0001635393 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 295,500 Underlying: Common Stock · 1,334 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting. F2 · derivative.exercise_date: Derivative securities vested in equal tranches, 1/3rd on December 2, 2020, 1/3rd on December 2, 2021 and 1/3rd on December 2, 2022. F3 · derivative.expiration_date: Shares of common stock are required to be delivered to the Reporting Person within sixty days of vesting. The final tranche of shares was delivered on December 6, 2022. Read SEC document |
| December 06, 2022 Filed Dec 8, 2022 22:01 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Exercise / conversionCommon Stock, par value $0.001 per share | 1,334 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001161697-22-000570 · form4.xml · nonDerivative · entry 1 Daly Richard J · CIK 0001635393 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting. Read SEC document |
| August 24, 2022 Filed Aug 26, 2022 21:01 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Exercise / conversionOptions to purchase common stock · Derivative | 40,000 | $0.00 Strike: $2.53 | $0.00 |
DisclosureSEC source: 0001161697-22-000415 · form4.xml · derivative · entry 2 Daly Richard J · CIK 0001635393 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 296,834 Underlying: Common Stock · 40,000 shares Expires 2022-12-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option was granted on December 30, 2015 and previously vested in two annual installments. Read SEC document |
| August 24, 2022 Filed Aug 26, 2022 21:01 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Exercise / conversionCommon stock, par value $0.001 per share | 40,000 | $2.53 | $101,200.00 |
DisclosureSEC source: 0001161697-22-000415 · form4.xml · nonDerivative · entry 1 Daly Richard J · CIK 0001635393 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,666 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 14, 2022 Filed Jun 14, 2022 16:58 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | GrantCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001385508-22-000088 · wf-form4_165524027803629.xml · nonDerivative · entry 1 Daly Richard J · CIK 0001635393 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,800 F1 · kind: 2,000 shares are represented by restricted stock units ("RSUs"). Each RSU represents the Reporting Person's right to receive one share of Common Stock of Issuer, subject to the vesting schedule: 100% vest on the one year anniversary date or the date of the 2023 Annual Shareholder Meeting, whichever is earlier, subject to the Reporting Person continuing as a service provider through each such date. F1 · shares: 2,000 shares are represented by restricted stock units ("RSUs"). Each RSU represents the Reporting Person's right to receive one share of Common Stock of Issuer, subject to the vesting schedule: 100% vest on the one year anniversary date or the date of the 2023 Annual Shareholder Meeting, whichever is earlier, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| February 14, 2022 Filed Feb 16, 2022 22:01 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | GrantRestricted Stock Units · Derivative | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001161697-22-000111 · form4.xml · derivative · entry 1 Daly Richard J · CIK 0001635393 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 336,834 Underlying: Common Stock · 12,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting. F2 · derivative.exercise_date: Derivative securities vest in equal tranches, 1/3rd on February 14, 2023, 1/3rd on February 14, 2024 and 1/3rd on February 14, 2025. F3 · derivative.expiration_date: Shares of common stock will be delivered to the Reporting Person within sixty (60) days of vesting. Read SEC document |
| January 25, 2022 Filed Jan 26, 2022 22:29 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Exercise / conversionOptions to purchase common stock · Derivative | 50,000 | $0.00 Strike: $3.35 | $0.00 |
DisclosureSEC source: 0001161697-22-000071 · form4.xml · derivative · entry 2 Daly Richard J · CIK 0001635393 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 324,834 Underlying: Common Stock · 50,000 shares Expires 2022-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Derivative securities vested in three equal tranches beginning on February 19, 2016. Read SEC document |
| January 25, 2022 Filed Jan 26, 2022 22:29 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Exercise / conversionCommon stock, par value $0.001 per share | 50,000 | $3.35 | $167,500.00 |
DisclosureSEC source: 0001161697-22-000071 · form4.xml · nonDerivative · entry 1 Daly Richard J · CIK 0001635393 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,666 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 28, 2021 Filed Dec 30, 2021 21:46 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | GrantOptions to purchase common stock · Derivative | 20,000 | $0.00 Strike: $7.07 | $0.00 |
DisclosureSEC source: 0001161697-21-000611 · form4.xml · derivative · entry 1 Daly Richard J · CIK 0001635393 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 374,834 Underlying: Common Stock · 20,000 shares Expires 2028-12-28 F1 · derivative.exercise_date: Derivative securities vest in equal tranches, 1/3rd on December 28, 2022, 1/3rd on December 28, 2023 and 1/3rd on December 28, 2024. Read SEC document |
| December 03, 2021 Filed Dec 6, 2021 22:10 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Exercise / conversionRestricted Stock Units · Derivative | 1,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001161697-21-000551 · form4.xml · derivative · entry 2 Daly Richard J · CIK 0001635393 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 354,834 Underlying: Common Stock · 1,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting. F2 · derivative.exercise_date: Derivative securities vest in equal tranches, 1/3rd on December 2, 2020, 1/3rd on December 2, 2021 and 1/3rd on December 2, 2022. F3 · derivative.expiration_date: Shares of common stock are required to be delivered to the Reporting Person within sixty days of vesting. The second tranche of shares was delivered on December 3, 2021. Read SEC document |
| December 03, 2021 Filed Dec 6, 2021 22:10 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Exercise / conversionCommon Stock, par value $0.001 per share | 1,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001161697-21-000551 · form4.xml · nonDerivative · entry 1 Daly Richard J · CIK 0001635393 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,666 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting. Read SEC document |
| June 15, 2021 Filed Jun 16, 2021 16:07 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | GrantStock Option (right to buy) · Derivative | 2,500 | $0.00 Strike: $13.30 | $0.00 |
DisclosureSEC source: 0001385508-21-000087 · wf-form4_162387400674324.xml · derivative · entry 2 Daly Richard J · CIK 0001635393 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 2,500 shares Expires 2031-06-14 F2 · kind: On June 15, 2021, the reporting person was granted 2,500 non-qualified stock options. 100% of the options vest on the one year anniversary of the grant date or the date of the 2022 Annual Shareholder Meeting, whichever is earlier, subject to the Reporting Person continuing as a service provider through such date. Read SEC document |
| June 15, 2021 Filed Jun 16, 2021 16:07 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | GrantCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001385508-21-000087 · wf-form4_162387400674324.xml · nonDerivative · entry 1 Daly Richard J · CIK 0001635393 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,800 F1 · kind: 2,000 shares are represented by restricted stock units ("RSUs"). Each RSU represents the Reporting Person's right to receive one share of Common Stock of Issuer, subject to the vesting schedule: 100% vest on the one year anniversary date or the date of the 2022 Annual Shareholder Meeting, whichever is earlier, subject to the Reporting Person continuing as a service provider through such date. Read SEC document |
| December 30, 2020 Filed Jan 4, 2021 21:32 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | GrantOptions to purchase common stock · Derivative | 30,000 | $0.00 Strike: $3.42 | $0.00 |
DisclosureSEC source: 0001161697-21-000007 · form4.xml · derivative · entry 1 Daly Richard J · CIK 0001635393 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 356,167 Underlying: Common Stock · 30,000 shares Expires 2027-12-30 F1 · derivative.exercise_date: Derivative securities vest in equal tranches, 1/3rd on December 30, 2021, 1/3rd on December 30, 2022 and 1/3rd on December 30, 2023. Read SEC document |
| December 22, 2020 Filed Dec 28, 2020 21:35 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Exercise / conversionRestricted Stock Units · Derivative | 1,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001161697-20-000598 · form4.xml · derivative · entry 2 Daly Richard J · CIK 0001635393 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 326,167 Underlying: Common Stock · 1,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting. F2 · derivative.exercise_date: Derivative securities vest in equal tranches, 1/3rd on December 2, 2020, 1/3rd on December 2, 2021 and 1/3rd on December 2, 2022. F3 · derivative.expiration_date: Shares of common stock will be delivered to the Reporting Person within sixty days of vesting. The first tranche of shares was delivered on December 22, 2020. Read SEC document |
| December 22, 2020 Filed Dec 28, 2020 21:35 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Exercise / conversionCommon Stock, par value $0.001 per share | 1,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001161697-20-000598 · form4.xml · nonDerivative · entry 1 Daly Richard J · CIK 0001635393 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting. Read SEC document |
| June 15, 2020 Filed Jun 15, 2020 16:16 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | GrantCommon Stock · Derivative | 2,500 | $0.00 Strike: $8.79 | $0.00 |
DisclosureSEC source: 0001385508-20-000079 · wf-form4_159225216729096.xml · derivative · entry 2 Daly Richard J · CIK 0001635393 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 2,500 shares Expires 2030-06-15 F2 · kind: On June 15, 2020, the Reporting Person was granted 2,500 non-qualified stock options. 100% of the options vest on the one year anniversary of the grant date or the date of the 2021 Annual Shareholder Meeting, whichever is earlier, subject to the Reporting Person continuing as a service provider through such date. F2 · derivative.exercise_date: On June 15, 2020, the Reporting Person was granted 2,500 non-qualified stock options. 100% of the options vest on the one year anniversary of the grant date or the date of the 2021 Annual Shareholder Meeting, whichever is earlier, subject to the Reporting Person continuing as a service provider through such date. Read SEC document |
| June 15, 2020 Filed Jun 15, 2020 16:16 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | GrantCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001385508-20-000079 · wf-form4_159225216729096.xml · nonDerivative · entry 1 Daly Richard J · CIK 0001635393 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,800 F1 · kind: 2,000 shares are represented by restricted stock units ("RSUs"). Each RSU represents the Reporting Person's right to receive one share of Common Stock of Issuer, subject to the vesting schedule: 100% vest on the one year anniversary date or the date of the 2021 Annual Shareholder Meeting, whichever is earlier, subject to the Reporting Person continuing as a service provider through each date. Read SEC document |
| December 02, 2019 Filed Dec 4, 2019 22:27 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | GrantRestricted Stock Units · Derivative | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001161697-19-000528 · form4.xml · derivative · entry 2 Daly Richard J · CIK 0001635393 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 327,500 Underlying: Common Stock · 4,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting. F1 · derivative.exercise_date: Derivative securities vest in equal tranches, 1/3rd on December 2, 2020, 1/3rd on December 2, 2021 and 1/3rd on December 2, 2022. F3 · derivative.expiration_date: Shares of common stock will be delivered to the Reporting Person upon vesting. Read SEC document |
| December 02, 2019 Filed Dec 4, 2019 22:27 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | GrantOptions to purchase common stock · Derivative | 33,500 | $0.00 Strike: $4.64 | $0.00 |
DisclosureSEC source: 0001161697-19-000528 · form4.xml · derivative · entry 1 Daly Richard J · CIK 0001635393 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 323,500 Underlying: Common Stock · 33,500 shares Expires 2026-12-02 F1 · derivative.exercise_date: Derivative securities vest in equal tranches, 1/3rd on December 2, 2020, 1/3rd on December 2, 2021 and 1/3rd on December 2, 2022. Read SEC document |
| September 12, 2019 Filed Mar 2, 2020 16:04 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | PurchaseCommon Stock | 1,800 | $13.90 | $25,020.00 |
DisclosureSEC source: 0001385508-20-000030 · wf-form4_158318302808179.xml · nonDerivative · entry 1 Daly Richard J · CIK 0001635393 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,800 Read SEC document |
| June 12, 2019 Filed Jun 13, 2019 16:11 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | GrantStock Option (right to buy) · Derivative | 2,500 | $0.00 Strike: $12.75 | $0.00 |
DisclosureSEC source: 0001385508-19-000065 · wf-form4_156045665674490.xml · derivative · entry 1 Daly Richard J · CIK 0001635393 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 2,500 shares Expires 2029-06-11 F1 · derivative.exercise_date: On June 12, 2019, the reporting person was granted 2,500 non-qualified stock options. 100% of the options vest on the one year anniversary of the grant date. Read SEC document |
| December 19, 2018 Filed Dec 21, 2018 21:48 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | GrantOptions to purchase common stock · Derivative | 25,000 | $0.00 Strike: $2.24 | $0.00 |
DisclosureSEC source: 0001161697-18-000626 · form4.xml · derivative · entry 2 Daly Richard J · CIK 0001635393 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 290,000 Underlying: Common Stock · 25,000 shares Expires 2025-12-19 Read SEC document |
| December 19, 2018 Filed Dec 21, 2018 21:48 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | GrantOptions to purchase common stock · Derivative | 25,000 | $0.00 Strike: $2.24 | $0.00 |
DisclosureSEC source: 0001161697-18-000626 · form4.xml · derivative · entry 1 Daly Richard J · CIK 0001635393 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265,000 Underlying: Common Stock · 25,000 shares Expires 2025-12-19 Read SEC document |
| June 12, 2018 Filed Jun 13, 2018 16:07 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | GrantStock Option (right to buy) · Derivative | 5,000 | $15.56 Strike: $15.56 | $77,800.00 |
DisclosureSEC source: 0001385508-18-000057 · wf-form4_152892042492264.xml · derivative · entry 1 Daly Richard J · CIK 0001635393 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2028-06-11 F1 · derivative.exercise_date: On June 12, 2018, the reporting person was granted an option to purchase 5,000 shares of common stock. The options vest as follows: 33% of the options vest on the first, second and third anniversary of the grant date. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 21:47 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | GrantOptions to purchase common stock · Derivative | 20,000 | $0.00 Strike: $4.01 | $0.00 |
DisclosureSEC source: 0001161697-18-000024 · form4.xml · derivative · entry 2 Daly Richard J · CIK 0001635393 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,000 Underlying: Common Stock · 20,000 shares Expires 2025-01-02 Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 21:47 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | GrantOptions to purchase common stock · Derivative | 20,000 | $0.00 Strike: $4.01 | $0.00 |
DisclosureSEC source: 0001161697-18-000024 · form4.xml · derivative · entry 1 Daly Richard J · CIK 0001635393 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,000 Underlying: Common Stock · 20,000 shares Expires 2025-01-02 Read SEC document |
| November 07, 2017 Filed Nov 9, 2017 21:00 UTC | PALISADE BIO, INC. CUR · Entity 5803 | GrantCommon Stock Purchase Option · Derivative | 100,000 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0001171843-17-006832 · formfour.xml · derivative · entry 1 Daly Richard J · CIK 0001635393 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2027-11-07 F1 · security: Represents a discretionary grant to Employee. The options vest quarterly on 2/718, 5/7/18, 8/7/18, and 11/7/18. Read SEC document |
| June 28, 2017 Filed Jun 30, 2017 17:09 UTC | SYNERGY PHARMACEUTICALS, INC. SGYP · Entity 164269 | GrantStock Options · Derivative | 62,500 | $0.00 Strike: $4.50 | $0.00 |
DisclosureSEC source: 0001104659-17-043016 · a4.xml · derivative · entry 1 Daly Richard J · CIK 0001635393 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,056 Underlying: Common Stock · 62,500 shares Expires 2027-06-28 Read SEC document |
| May 17, 2017 Filed May 18, 2017 17:02 UTC | PALISADE BIO, INC. CUR · Entity 5803 | PurchaseCommon Stock | 7,500 | $4.00 | $30,000.00 |
DisclosureSEC source: 0001171843-17-003169 · formfour.xml · nonDerivative · entry 1 Daly Richard J · CIK 0001635393 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,312 F1 · security: Reporting person, Richard Daly, purchased 7,500 shares of common stock in a private transaction directly from the issuer on May 17, 2017. Read SEC document |
| February 24, 2017 Filed Feb 27, 2017 21:30 UTC | PALISADE BIO, INC. CUR · Entity 5803 | PurchaseCommon Stock | 2,591 | $3.86 | $10,001.26 |
DisclosureSEC source: 0001171843-17-001161 · form4.xml · nonDerivative · entry 1 Daly Richard J · CIK 0001635393 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,812 F1 · security: Reporting person, Richard Daly, purchased 2,591 shares of common stock in a private transaction directly from the issuer. Read SEC document |
| January 25, 2017 Filed Jan 27, 2017 21:18 UTC | PALISADE BIO, INC. CUR · Entity 5803 | PurchaseCommon Stock | 2,841 | $3.52 | $10,000.32 |
DisclosureSEC source: 0001171843-17-000498 · form4daly.xml · nonDerivative · entry 1 Daly Richard J · CIK 0001635393 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,221 F1 · security: Reporting person, Richard Daly, purchased 2,841 shares of common stock in a private transaction directly from the issuer. Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 22:06 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | GrantOptions to purchase common stock · Derivative | 30,000 | $0.00 Strike: $1.13 | $0.00 |
DisclosureSEC source: 0001161697-17-000008 · form4.xml · derivative · entry 2 Daly Richard J · CIK 0001635393 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 30,000 shares Expires 2024-01-03 Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 22:06 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | GrantOptions to purchase common stock · Derivative | 30,000 | $0.00 Strike: $1.13 | $0.00 |
DisclosureSEC source: 0001161697-17-000008 · form4.xml · derivative · entry 1 Daly Richard J · CIK 0001635393 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,000 Underlying: Common Stock · 30,000 shares Expires 2024-01-03 Read SEC document |
| December 23, 2016 Filed Dec 30, 2016 21:05 UTC | PALISADE BIO, INC. CUR · Entity 5803 | PurchaseCommon Stock | 32,259 | $0.31 | $10,000.29 |
DisclosureSEC source: 0001171843-16-013813 · formfour.xml · nonDerivative · entry 1 Daly Richard J · CIK 0001635393 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,939 F1 · security: Reporting person, Richard Daly, purchased 32,259 shares of common stock in a private transaction directly from the issuer. Read SEC document |
| November 25, 2016 Filed Nov 28, 2016 22:36 UTC | PALISADE BIO, INC. CUR · Entity 5803 | PurchaseCommon Stock | 35,715 | $0.28 | $10,000.20 |
DisclosureSEC source: 0001171843-16-013393 · formfour.xml · nonDerivative · entry 1 Daly Richard J · CIK 0001635393 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,680 F1 · security: Reporting person, Richard Daly, purchased 35,715 shares of common stock in a private transaction directly from the issuer. Read SEC document |
| October 25, 2016 Filed Oct 27, 2016 20:05 UTC | PALISADE BIO, INC. CUR · Entity 5803 | PurchaseCommon Stock | 35,715 | $0.28 | $10,000.20 |
DisclosureSEC source: 0001171843-16-012678 · formfour.xml · nonDerivative · entry 1 Daly Richard J · CIK 0001635393 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,965 F1 · security: Reporting person, Richard Daly, purchased 35,715 shares of common stock in a private transaction directly from the issuer. Read SEC document |
| September 23, 2016 Filed Sep 26, 2016 20:50 UTC | PALISADE BIO, INC. CUR · Entity 5803 | PurchaseCommon Stock | 31,250 | $0.32 | $10,000.00 |
DisclosureSEC source: 0001171843-16-012274 · f4_092616daly.xml · nonDerivative · entry 1 Daly Richard J · CIK 0001635393 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,250 F1 · security: Reporting person, Richard Daly, purchased 31,250 shares of common stock in a private transaction directly from the issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.